Trade FibroGen, Inc - FGEN CFD

Add to favourite

0.34

5.56%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.05

Long position overnight fee

-0.024151%

Short position overnight fee

0.001929%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.36
Open	0.34
1-Year Change	-20.93%
Day's Range	0.34 - 0.34

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Nov 15, 2024	0.34	0.00	0.00%	0.34	0.34	0.34
Nov 14, 2024	0.36	0.01	2.86%	0.35	0.36	0.34
Nov 13, 2024	0.30	-0.09	-23.08%	0.39	0.39	0.20
Nov 12, 2024	0.35	0.03	9.37%	0.32	0.36	0.32
Nov 11, 2024	0.32	0.01	3.23%	0.31	0.33	0.31
Nov 1, 2024	0.28	0.00	0.00%	0.28	0.28	0.28
Oct 31, 2024	0.29	0.00	0.00%	0.29	0.29	0.29
Oct 29, 2024	0.28	0.00	0.00%	0.28	0.28	0.28
Oct 25, 2024	0.32	0.00	0.00%	0.32	0.32	0.32
Oct 24, 2024	0.31	0.00	0.00%	0.31	0.31	0.31
Oct 23, 2024	0.33	-0.01	-2.94%	0.34	0.34	0.33
Oct 22, 2024	0.32	-0.04	-11.11%	0.36	0.36	0.32
Oct 21, 2024	0.35	-0.03	-7.89%	0.38	0.38	0.34
Oct 18, 2024	0.38	0.01	2.70%	0.37	0.38	0.36
Oct 17, 2024	0.35	0.00	0.00%	0.35	0.35	0.35
Oct 16, 2024	0.35	0.01	2.94%	0.34	0.35	0.34
Oct 15, 2024	0.34	0.00	0.00%	0.34	0.34	0.34
Oct 14, 2024	0.34	0.01	3.03%	0.33	0.34	0.33
Oct 11, 2024	0.32	0.00	0.00%	0.32	0.32	0.32
Oct 10, 2024	0.30	0.00	0.00%	0.30	0.30	0.30

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

FibroGen, Inc Company profile

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.

Industry:

Biotechnology & Medical Research (NEC)

409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US

News

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

08:36, 15 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024